// App-Quantinova.ai

4207 : Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Researchers

Presenter

  • Rainer Storb

Principal Investigators

  • Thomas Chauncey

  • David G. Maloney

  • Barry Storer

  • Brenda M. Sandmaier

Medical Centers

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Chronic Lymphocytic Leukemia

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Myelofibrosis

  • Lymphomas

Biomarkers

  • Hematocrit

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Ovastat

  • Busulfan

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved